Analyzing published datasets of DLBCL, the most common aggressive B-cell lymphoma [27, 28, 37], we confirmed that elevated CXCR4 expression correlates with adverse prognosis (Supplementary Fig. S5a) and that CXCR4 mutations are present, but rare, in DLBCL patients (Supplementary Figure S5b and Supplementary Table T3). This evidence concerns the gene CXCR4 and B-cell non-Hodgkin lymphoma.